journal article·2025-09Open access

A bioprinted breast cancer model using bioinks of decellularized breast tissue for studying cancer stemness, invasion, and drug efficacy

Barbara Blanco-Fernandez, Gulsun Bagci, Soledad Perez-Amodio, Sergi Rey-Vinolas, Celia Ximenes-Carballo, Uxia Gato-Diaz, Angel Concheiro, Carmen Alvarez-Lorenzo, Elisabeth Engel

Acta Biomaterialia· Volume 203

Abstract

Breast cancer 3D in vitro systems that replicate key tumor characteristics could assist drug discovery by providing more clinically translational models. Breast tumors are formed by hierarchically organized cancer and stromal cells and the extracellular matrix, all of which contribute to the disease progression and treatment response. 3D-bioprinting has enabled the creation of anatomically relevant constructs that better recapitulate the tumor architecture. The extracellular matrix's role in the tumor outcome has motivated the development of biomimetic bioinks. Among them, bioinks based on decellularized mammary glands can mimic many native biological cues. This work aims to develop a bioprinted 3D in vitro model of breast cancer using a biomimetic bioink based on decellularized mammary glands, and to investigate the effect of this bioink on the malignancy and drug resistance of breast cancer cells. The biomimetic bioink supported cell stemness, invasion, and an immunosuppressive environment but did not promote drug resistance. We also tested the effect of supplementing the bioink with collagen I, which is highly expressed in breast cancer, on breast cancer cells. We observed a higher expression of malignancy markers (COL1A1) and invasion markers (CDH2, MMP2). Next, we bioprinted a cancer model using human adipose mesenchymal stem cells and breast cancer cells to replicate tumor anatomy. These bioprinted models exhibited enhanced resistance to doxorubicin, particularly in the case of the bioink supplemented with collagen I. Therefore, supplementing the bioink with collagen I can promote the creation of more relevant cancer models for drug screening. STATEMENT OF SIGNIFICANCE: Bioprinted 3D in vitro tumor models are emerging as key tools for drug discovery, as they effectively replicate key tumor characteristics. We developed a bioprinted breast cancer model replicating the tumor structure and extracellular matrix, using a biomimetic bioink based on decellularized mammary glands (TDM) and collagen I. The model consisted of a core of cancer cells surrounded by a layer of mesenchymal stem cells (MSCs). Our findings indicate that TDM-based bioinks enhanced the malignant behavior of the breast cancer cells and promoted the differentiation of MSCs towards cancer-associated fibroblasts. Moreover, cancer cells exhibited increased resistance to chemotherapy in this model, highlighting the importance of mimicking the tumor structure and extracellular matrix in creating more physiologically relevant tumor models.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Cell Image Analysis Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (78)

Show source-provided references
1. Breast cancer models: engineering the tumor microenvironment10.1016/j.actbio.2020.02.006 ↗
3. Proteinaceous hydrogels for bioengineering advanced 3D tumor models
4. G. Bağcı, C. Ximenes-Carballo, S. Perez-Amodio, O. Castaño, E. Engel, B. Blanco-Fernandez, Advanced 3D in vitro models to recapitulate the breast tumor microenvironment, in: 2022. https://doi.org/10.1007/16833_2022_56.10.1007/16833_2022_56 ↗
5. Tumor microenvironment in breast cancer—Updates on therapeutic implications and pathologic assessment10.3390/cancers13164233 ↗
6. Mesenchymal stem/stromal cells in breast cancer development and management10.1016/j.semcancer.2022.09.002 ↗
7. Concepts of extracellular matrix remodelling in tumour progression and metastasis10.1038/s41467-020-18794-x ↗
8. Role of extracellular matrix in breast cancer development: a brief update10.12688/f1000research.14133.2 ↗
9. The extracellular matrix in breast cancer10.1016/j.addr.2015.12.017 ↗
10. Microenvironmental regulation of tumor progression and metastasis10.1038/nm.3394 ↗
11. The role of the extracellular matrix in cancer stemness10.3389/fcell.2019.00086 ↗
12. Charting the unexplored extracellular matrix in cancer10.1111/iep.12269 ↗
13. Modeling tumor phenotypes in vitro with three-dimensional bioprinting10.1016/j.celrep.2018.12.090 ↗
14. 3D bioprinting for reconstituting the cancer microenvironment
15. 3D bioprinting of engineered breast cancer constructs for personalized and targeted cancer therapy10.1016/j.jconrel.2021.03.026 ↗
16. Extracellular matrix hydrogels from decellularized tissues: structure and function10.1016/j.actbio.2016.11.068 ↗
17. Distinct phenotypes of cancer cells on tissue matrix gel10.1186/s13058-020-01321-7 ↗
18. 3D bioprinted mammary organoids and tumoroids in human mammary derived ECM hydrogels10.1016/j.actbio.2019.06.017 ↗
19. Decellularization of tumours: a new frontier in tissue engineering10.1177/20417314221091682 ↗
20. Organotypic 3D decellularized matrix tumor spheroids for high-throughput drug screening10.1016/j.biomaterials.2021.120983 ↗
21. Decellularized extracellular matrix for bioengineering physiomimetic 3D in vitro tumor models10.1016/j.tibtech.2020.04.006 ↗
22. Bioprinting decellularized breast tissue for the development of 3D breast cancer models10.1021/acsami.2c00920 ↗
23. Preparation of ready-to-use, storable and reconstituted type I collagen from rat tail tendon for tissue engineering applications10.1038/nprot.2006.430 ↗
24. Engineered microtissues for the bystander therapy against cancer10.1016/j.msec.2020.111854 ↗
25. Predicting bulk mechanical properties of cellularized collagen gels using multiphoton microscopy10.1016/j.actbio.2010.07.004 ↗
26. Hybrid collagen alginate hydrogel as a platform for 3D tumor spheroid invasion10.1016/j.actbio.2018.06.003 ↗
27. Scaffold stiffness influences breast cancer cell invasion via EGFR-linked Mena upregulation and matrix remodeling10.1016/j.matbio.2019.07.006 ↗
28. Decoupling the effects of stiffness and fiber density on cellular behaviors via an interpenetrating network of gelatin-methacrylate and collagen10.1016/j.biomaterials.2017.06.039 ↗
29. Cancer invasion: patterns and mechanisms10.32607/20758251-2015-7-2-17-28 ↗
30. Cdc42–MRCK and Rho–ROCK signalling cooperate in myosin phosphorylation and cell invasion10.1038/ncb1230 ↗
31. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE10.1038/ncb1675 ↗
32. Extracellular matrix determinants of proteolytic and non-proteolytic cell migration10.1016/j.tcb.2011.09.006 ↗
33. Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis10.1007/s12195-021-00694-9 ↗
34. The role of snail in EMT and tumorigenesis10.2174/15680096113136660102 ↗
35. A mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis10.1016/j.devcel.2008.09.003 ↗
36. Mechanotransduction pathways in regulating epithelial-mesenchymal plasticity10.1016/j.ceb.2023.102245 ↗
37. Cancer stem cells—origins and biomarkers: perspectives for targeted personalized therapies10.3389/fimmu.2020.01280 ↗
38. CD44 as a tumor biomarker and therapeutic target10.1186/s40164-020-00192-0 ↗
39. CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis10.1186/bcr1610 ↗
40. Cancer stem cell signaling pathways10.1097/MD.0000000000004765 ↗
41. The transcriptional and signalling networks of pluripotency10.1038/ncb0511-490 ↗
42. Characterization of the stemness potency of mammospheres isolated from the breast cancer cell lines10.1177/1010428319869101 ↗
43. SIPA1 enhances SMAD2/3 expression to maintain stem cell features in breast cancer cells10.1016/j.scr.2020.102099 ↗
44. SOX9: the master regulator of cell fate in breast cancer10.1016/j.bcp.2019.113789 ↗
45. Angiogenic signaling pathways and anti-angiogenic therapy for cancer10.1038/s41392-023-01460-1 ↗
46. Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity10.1111/cas.13433 ↗
47. Mesenchymal stem cells relevance in multicellular bioengineered 3D in vitro tumor models10.1002/biot.201700079 ↗
48. Adipose-derived stem/stromal cell secretome modulates breast cancer cell proliferation and differentiation state towards aggressiveness10.1016/j.biochi.2021.08.010 ↗
49. Stiffness-dependent MSC homing and differentiation into CAFs – implications for breast cancer invasion10.1242/jcs.261145 ↗
50. Mesenchymal stem cell-induced DDR2 mediates stromal-breast cancer interactions and metastasis growth10.1016/j.celrep.2016.12.079 ↗
51. Mechano-signal transduction in mesenchymal stem cells induces prosaposin secretion to drive the proliferation of breast cancer cells10.1158/0008-5472.CAN-17-0569 ↗
52. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures10.1186/s12935-022-02599-7 ↗
53. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells10.1016/j.ccr.2011.12.024 ↗
54. The biomimetic extracellular matrix: a therapeutic tool for breast cancer research10.1016/j.trsl.2021.11.008 ↗
55. Extracellular matrix components in breast cancer progression and metastasis10.1016/j.breast.2013.07.012 ↗
56. Brain organoid formation on decellularized porcine brain ECM hydrogels10.1371/journal.pone.0245685 ↗
57. Decellularized tissues as platforms for in vitro modeling of healthy and diseased tissues10.1016/j.actbio.2020.05.031 ↗
58. Decellularized breast matrix as bioactive microenvironment for in vitro three-dimensional cancer culture10.1002/jcp.26782 ↗
59. Human decellularized adipose tissue scaffold as a model for breast cancer cell growth and drug treatments10.1016/j.biomaterials.2014.03.003 ↗
60. Human breast cancer decellularized scaffolds promote epithelial-to-mesenchymal transitions and stemness of breast cancer cells in vitro10.1002/jcp.27630 ↗
61. Decellularized extracellular matrix scaffolds identify full-length collagen VI as a driver of breast cancer cell invasion in obesity and metastasis10.1126/sciadv.abc3175 ↗
62. Tissue architecture in tumor initiation and progression10.1016/j.trecan.2022.02.007 ↗
63. H.D. Dawson, A comparative assessment of the pig, mouse and human genomes, in: In The Minipig in Biomedical Research, 1st ed., CRC Press, US, 2011: pp. 323–42.10.1201/b11356-28 ↗
64. Mechanoresponsive metabolism in cancer cell migration and metastasis10.1016/j.cmet.2021.04.002 ↗
65. The host response to naturally-derived extracellular matrix biomaterials10.1016/j.smim.2017.01.002 ↗
66. Isotropic 3D nuclear morphometry of normal, fibrocystic and malignant breast epithelial cells reveals new structural alterations10.1371/journal.pone.0029230 ↗
67. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast
68. Effect of capillary fluid flow on single cancer cell cycle dynamics, motility, volume and morphology10.1039/D2LC00322H ↗
69. Matrix pore size governs escape of human breast cancer cells from a microtumor to an empty cavity10.1016/j.isci.2020.101673 ↗
70. Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression10.1038/s41418-023-01166-5 ↗
71. Immune modulatory properties of collagen in cancer10.3389/fimmu.2021.791453 ↗
72. Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression10.1016/j.ajpath.2013.06.026 ↗
73. IL-6/JAK/STAT3 signaling in breast cancer metastasis: biology and treatment10.3389/fonc.2022.866014 ↗
74. Tumor collagens predict genetic features and patient outcomes10.1038/s41525-023-00358-9 ↗
75. Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression10.1038/s41467-022-31340-1 ↗
76. Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology10.1186/s13046-021-01908-8 ↗
77. Flow-on-repellent biofabrication of fibrous decellularized breast tumor-stroma models10.1016/j.bioadv.2024.214058 ↗
78. Organotypic 3D decellularized matrix tumor spheroids for high-throughput drug screening10.1016/j.biomaterials.2021.120983 ↗